Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2021, Vol. 35 ›› Issue (1): 99-103.doi: 10.6040/j.issn.1673-3770.0.2020.250

Previous Articles     Next Articles

Preoperative timing and the effect of intravitreal aflibercept injection for proliferative diabetic retinopathy patients

LIU Zhigao1,2, WANG Shuya1, HAN Xuguang2, WANG Yu2, LI Zhiwei2, MA Aihua3, ZHAO Bojun1,3   

  1. 1. Department of Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan 250300, Shandong, China;
    2. Department of Ophthalmology, Jinan Aier Eye Hospital, Jinan 250100, Shandong, China;
    3. Department of Ophthalmology, Provincial Hospital Affiliated to Shandong University, Jinan 250000, Shandong, China
  • Published:2021-02-01

PDF (PC)

321

Abstract: Objective To investigate the changes in vitreous inflammatory and angiogenic cytokine levels after administering intravitreal aflibercept(IVA)in the eyes with proliferative diabetic retinopathy(PDR). Methods A prospective comparative study was performed of the clinical data of the PDR patients who had undergone 23-gauge vitrectomy. Patients were divided into three groups: group A(16 eyes of 16 patients), without IVA administered preoperatively; group B(18 eyes of 18 patients), with IVA 2.0 mg administered 3 days preoperatively; and group C(18 eyes of 18 patients), with IVA 2.0 mg administered 6 days preoperatively. A total of 15 patients with idiopathic epiretinal membrane or idiopathic macular hole were selected as controls(group D). The vitreous humor was collected at the beginning of vitrectomy. The vitreal factors, including the vascular endothelial growth factor(VEGF)and basic fibrosis growth factor, were measured using the cytometric bead array. Results Higher levels of VEGF(P<0.05)in groups A, B, and C were observed compared to group D. However, VEGF levels were significantly higher in group A than in groups B and C(P<0.05). Conclusions IVA is effective in reducing the level of VEGF. IVA administered 3 to 6 days preoperatively is optimal and can help reduce complications.

Key words: Neovascularization, Proliferative diabetic retinopathy, Angiogenic and inflammatory cytokines, Vitrectomy, Aflibercept

CLC Number: 

  • R774
[1] 李维业, 黎晓新, 徐国彤. 糖尿病性视网膜病变[M]. 北京: 人民卫生出版社, 2017: 224-225.
[2] Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis[J]. Retina, 2015, 35(10): 1931-1942. doi:10.1097/IAE.0000000000000723.
[3] Bressler SB, Liu DN, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab[J]. JAMA Ophthalmol, 2017, 135(6): 558-568. doi:10.1001/jamaophthalmol.2017.0821.
[4] Raczyńska D, Lisowska KA, Pietruczuk K, et al. The level of cytokines in the vitreous body of severe proliferative diabetic retinopathy patients undergoing posterior vitrectomy[J]. Curr Pharm Des, 2018, 24(27): 3276-3281. doi:10.2174/1381612824666180926110704.
[5] Dong F, Yu CY, Ding HY, et al. Evaluation of intravitreal ranibizumab on the surgical outcome for diabetic retinopathy with tractional retinal detachment[J]. Medicine(Baltimore), 2016, 95(8): e2731. doi:10.1097/MD.0000000000002731.
[6] Feng J, Li B, Wen J, et al. Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients[J]. Ophthalmic Res, 2018, 60(4): 250-257. doi:10.1159/000493640.
[7] Semeraro F, Cancarini A, dell'Omo R, et al. Diabetic retinopathy: vascular and inflammatory disease[J]. J Diabetes Res, 2015, 2015: 582060. doi:10.1155/2015/582060.
[8] Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor(anti-VEGF)in the management of proliferative diabetic retinopathy[J]. Drugs Context, 2018, 7: 212532. doi:10.7573/dic.212532.
[9] Pérez-Argandoña E, Verdaguer J, Zacharías S, et al. Preoperative intravitreal bevacizumab for proliferative diabetic retinopathy patients undergoing vitrectomy-First update[J]. Medwave, 2019, 19(1): e7512. doi:10.5867/medwave.2019.01.7511.
[10] Aleman I, Castillo Velazquez J, Rush SW, et al. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial[J]. Br J Ophthalmol, 2019, 103(12): 1740-1746. doi:10.1136/bjophthalmol-2018-313313.
[11] El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications[J]. Ophthalmology, 2011, 118(4): 636-641. doi:10.1016/j.ophtha.2010.08.038.
[12] Tsubota K, Usui Y, Wakabayashi Y, et al. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy[J]. Clin Ophthalmol, 2019, 13: 1063-1070. doi:10.2147/OPTH.S203921.
[13] 刘万智, 陈珺, 樊长春. 康柏西普治疗增生性糖尿病视网膜病变[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 88-91. doi: 10.6040/j.issn.1673-3770.0.2018.005. LIU Wanzhi, CHEN Jun, FAN Changchun. Clinical study of conbercept in the treatment of-proliferative diabetic retinopathy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 88-91. doi: 10.6040/j.issn.1673-3770.0.2018.005.
[14] 周学义, 李一鸣, 王美菊, 等. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89. doi: 10.6040/j.issn.1673-3770.0.2017.023. ZHOU Xueyi, LI Yiming, WANG Meiju, et al. The application of 25-gauge minimally invasive vitreoretinal surgery combined with intravitreal ranibizumab injections in the treatment of proliferative diabetic retinopathy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(4): 87-89. doi: 10.6040/j.issn.1673-3770.0.2017.023.
[15] Lotfy A, Solaiman KAM, Abdelrahman A, et al. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion[J]. Retina, 2018, 38(9): 1795-1800. doi:10.1097/IAE.0000000000001782.
[16] Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. doi:10.1016/j.ophtha.2016.07.032.
[17] Jiao CH, Eliott D, Spee C, et al. Apoptosis and angiofibrosis in diabeic tractional membranes after vascular endothelial growth factor inhibition: results of a prospective trial. report No. 2[J]. Retina, 2019, 39(2): 265-273. doi:10.1097/IAE.0000000000001952.
[18] Zlotcavitch L, Flynn HW Jr, Avery RL, et al. Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy[J]. Clin Ophthalmol, 2015, 9: 69-71. doi:10.2147/OPTH.S69466.
[19] Feng J, Li B, Wen J, et al. Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients[J]. Ophthalmic Res, 2018, 60(4): 250-257. doi:10.1159/000493640.
[20] Sohn EH, He SK, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment[J]. Arch Ophthalmol, 2012, 130(9): 1127. doi:10.1001/archophthalmol.2012.1611.
[21] Schlingemann RO, van Geest RJ, Lesnik Oberstein SY, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2012. doi:10.1111/j.1755-3768.2012.4723.x
[22] Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Cochrane Database Syst Rev, 2011(5): CD008214. doi:10.1002/14651858.cd008214.pub2.
[23] Sohn EH, He S, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1[J]. Arch Ophthalmol, 2012, 130(9): 1127-1134. doi:10.1001/archophthalmol.2012.1611.
[24] Han XX, Guo CM, Li Y, et al. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α[J]. Mol Vis, 2012, 18: 1-9. doi: 10.4236/ojog.2014.416149.
[25] Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Cochrane Database Syst Rev, 2015(8): CD008214. doi:10.1002/14651858.CD008214.pub3.
[26] Hueber A, Wiedemann P, Esser P, et al. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders(PVR and PDR)[J]. Int Ophthalmol, 1996, 20(6): 345-350. doi:10.1007/BF00176889.
[27] Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2[J]. The International Journal of Biochemistry & Cell Biology, 2000, 32(3): 263-267. doi: 10.1016/S1357-2725(99)00133-8.
[28] Li JK, Wei F, Jin XH, et al. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab[J]. Int J Ophthalmol, 2015, 8(6): 1202-1206. doi:10.3980/j.issn.2222-3959.2015.06.22.
[29] Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Group Study[J]. Clin Cancer Res, 2008, 14(5): 1407-1412. doi:10.1158/1078-0432.CCR-07-1154.
[1] ZHANG Taoran, WANG Wei, LI Mingming, HUANG Yingxiang. Subfoveal choroidal thickness changes following intravitreal ranibizumab treatment in choroidal neovascularization due to pathological myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 68-71.
[2] LU Wenrui, YAN Duan, XU Nuo. Surgical clinical treatment outcomes of 25 gauge vitrectomy for superior rhegmatogenous retinal detachment with air tamponade [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(6): 89-91.
[3] Pathologic myopia(PM)is a major cause of vision loss worldwide, particularly in Asian countries. Choroidal neovascularization(CNV)is a severe complication of PM, which can cause macular disorders, leading to central scotoma, metamorphopsia, visual field loss, and finally blindness if not treated. The advents of optical coherence topography(OCT), OCT angiography, and fundus fluorescein angiography are helpful in diagnosing CNV due to PM, which can show the position and size of CNV, whether active or passive. For the treatment, photodynamic and anti-vascular endothelial growth factor(anti-VEGF)therapies are widely applied. In recent years, administering the intravitreal anti-VEGF injection has become the first-line treatment for CNV secondary to PM. Many clinical studies have indicated that intravitreal anti-VEGF injections affect antagonizing neovascularization and reduce macular edema, thereby contributing to visual improvements and better long-term outcomes. This article provides an overview of the current diagnosis and treatment options for myopic CNV.. Diagnosis and treatment of choroidal neovascularization in pathologic myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 157-162.
[4] WANG Xinjuan, SHA Shike, MA Lusheng. A case of transient monocular visual loss after vitrectomy for diabetic retinopathy [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 171-172.
[5] LIU Wanzhi, CHEN Jun, FAN Changchun. Clinical study of conbercept in the treatment of proliferative diabetic retinopathy [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 88-91.
[6] ZHOU Xueyi, LI Yiming, WANG Meiju, ZHANG Yuanyuan, ZHANG Lizhuo. The application of 25-gauge minimally invasive vitreoretinal surgery combined with intravitreal ranibizumab injections in the treatment of proliferative diabetic retinopathy. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 87-89.
[7] . Causes of non-traumatic vitreous hemorrhage and effects of surgical treatment. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 107-109.
[8] HU Xinmiao. Effectiveness and safety of retinal photocoagulation in combination with vitrectomy for proliferative diabetic retinopathy [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(6): 74-77.
[9] ZHANG Ying-chun, DU Xiang-ge, YAN Xin, WANG Cui, ZHAO Bo-jun. Effect of nicotine on human RPE cells and HUVECs [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(2): 74-80.
[10] LIU Hai-yang, LI Su-yan, ZHANG Zheng-pei, FAN Wei. Comparison of improved membrane dissection and bimanual enbloc excision in 23G vitrectomy to treat proliferative diabetic retinopathy [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(1): 52-55.
[11] GONG Bin, FAN Chuan-feng, WANG Yu. Anti VEGF drugs(lucentis) to treat different courses of wet age-related maculardegeneration (62 cases report) [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(5): 58-61.
[12] ZI Yu-meng1, WANG Yu2, FAN Chuan-feng2, SHU Xiang-wen2, WU Chang-long2. Intravitreal injection of Ranibizumab for idiopathic choroidal neovascularization lesion in two courses [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(3): 63-66.
[13] LI Hao, ZHOU Fang. Idiopathic macular hole surgery prognosis based on macular hole size [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(2): 81-83.
[14] LIU Min1, GUO Jian-lian1， ZHANG Hua2. Vitrectomy in treating idiopathic macular epiretinal membrane [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(5): 65-67.
[15] LIU Bei1, ZHU Zhong-qiao1， DU Shan-shuang1， WANG Li-li2， YANG Xin-guang1. Effect of prior laser and triamcinolone acetonide on vitrectomy of proliferative diabetic retinopathy [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 66-68.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(2): 116 -118 .
[2] ZHOU Zi-ning,JIN Guo-wei . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(5): 462 -465 .
[3] ZHOU Bin,LI Bin . Endoscopic sinus surgery for 75 patients with chronic sinusitis and nasal polyps[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 24 -26 .
[4] XU Sainan,YANG Lei . Apoptosis of epithelial cells in nasal polyps promoted by erythromycin[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 27 -29 .
[5] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 94 -95 .
[6] LIU Lian-he . Treatment of deep neck abscess in 37 cases[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(2): 180 -181 .
[7] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 200 -203 .
[8] QIAO Yi,NI Guan-sen,CHEN Wen-wen . Effect of H-UPPP and nasal operations on obstructive sleep apnea syndrome in 38 cases
[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 206 -208 .
[9] WANG Xiao-feng,LIN Chang,CHENG Jin-mei . Expression of ABAD in inner ears and its clinical significance in different age mice[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 207 -211 .
[10] FAN Qi-jun,HUANG Zhi-wu,MEI Ling,XIAO Bo-kui . Expression of the heat shock protein 27 in rat cochlea induced by sodium salicylate injection by the FQ-PCR technique[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 212 -214 .
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd